A Randomized Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP vs R-CHOP in Treatment-Naive Subjects with High Risk Diffuse Large B-Cell Lymphoma Who Possess the Genomic Biomarker DGM1 (ENGINE Study) (Pharmatech DLBC-JIT)

A Randomized Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP vs R-CHOP in Treatment-Naive Subjects with High Risk Diffuse Large B-Cell Lymphoma Who Possess the Genomic Biomarker DGM1 (ENGINE Study) (Pharmatech DLBC-JIT)

Trial Category:
Lymphoma
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE

This study is evaluating the use of Enzastaurin with the drug combination R-CHOP for patients diagnosed with Diffuse Large B-Cell Lymphoma who possess a certain marker, and who have not been previously treated.  
Patients are "randomized" on this study.  This means a computer tells the study team which treatment you will receive.  Neither the patient or the physician can choose the treatment assignment.  The purpose of Randomized trials is to equally study both treatment options using the same criteria in order to identify if one treatment may be superior to another treatment. 

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members